Work

A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers

Year: 2023

Type: article

Study design: Clinical Trial

Source: International Journal of Gynecological Cancer

DOI: 10.1136/ijgc-2023-004491

Authors: Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, James L. Abbruzzese, Eugenia Girda, Rachel W. Miller, Jennifer Croke, Helen Mackay, Yeh Chen Lee, Valerie Bowering, Janelle Ramsahai, Lisa Wang, April D'Souza, Charles A. Kunos, Amit M. Oza, Stephanie Lheureux

Institutions: Princess Margaret Cancer Centre, University of Colorado Anschutz, Duke University, Duke Cancer Institute, Rutgers Cancer Institute, University of Kentucky, Markey Cancer Center, Sunnybrook Health Science Centre, Odette Cancer Centre, UNSW Sydney, National Cancer Institute

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Pfizer, AstraZeneca, Gilead Sciences, Regeneron Pharmaceuticals, Novocure, Seagen, Eisai, MorphoSys, National Cancer Institute

Awards: G8549699457, North American Star Consortium, The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies

OpenAlex ID: W4382396967

FWCI: 4.379

Cites: 35

Cited by: 16

Related to: 10